Matches in Ubergraph for { <http://purl.obolibrary.org/obo/NCIT_C66944> ?p ?o ?g. }
Showing items 1 to 58 of
58
with 100 items per page.
- NCIT_C66944 IAO_0000115 "An antibody-drug conjugate (ADC) directed against the tumor necrosis factor (TNF) receptor CD30 with potential antineoplastic activity. Brentuximab vedotin is generated by conjugating the chimeric anti-CD30 monoclonal antibody SGN-30 to the cytotoxic agent monomethyl auristatin E (MMAE) via a valine-citrulline peptide linker. Upon administration and internalization by CD30-positive tumor cells, brentuximab vedotin undergoes enzymatic cleavage, releasing MMAE into the cytosol; MMAE binds to tubulin and inhibits tubulin polymerization, which may result in G2/M phase arrest and tumor cell apoptosis. Transiently activated during lymphocyte activation, CD30 (tumor necrosis factor receptor superfamily, member 8;TNFRSF8) may be constitutively expressed in hematologic malignancies including Hodgkin lymphoma and some T-cell non-Hodgkin lymphomas. The linkage system in brentuximab vedotin is highly stable in plasma, resulting in cytotoxic specificity for CD30-positive cells." @default.
- NCIT_C66944 NCIT_A32 NCIT_C1909 @default.
- NCIT_C66944 NCIT_A7 NCIT_C38906 @default.
- NCIT_C66944 NCIT_NHC0 "C66944" @default.
- NCIT_C66944 NCIT_P106 "Pharmacologic Substance" @default.
- NCIT_C66944 NCIT_P107 "Brentuximab Vedotin" @default.
- NCIT_C66944 NCIT_P108 "Brentuximab Vedotin" @default.
- NCIT_C66944 NCIT_P207 "C2932409" @default.
- NCIT_C66944 NCIT_P210 "914088-09-8" @default.
- NCIT_C66944 NCIT_P302 "Hodgkin lymphoma (HL); anaplastic large cell lymphoma (ALCL); other CD30-expressing peripheral T-cell lymphomas" @default.
- NCIT_C66944 NCIT_P319 "7XL5ISS668" @default.
- NCIT_C66944 NCIT_P322 "CTRP" @default.
- NCIT_C66944 NCIT_P322 "FDA" @default.
- NCIT_C66944 NCIT_P322 "GDC" @default.
- NCIT_C66944 NCIT_P322 "PCDC" @default.
- NCIT_C66944 NCIT_P329 "530758" @default.
- NCIT_C66944 NCIT_P330 "530758" @default.
- NCIT_C66944 NCIT_P350 "C68H106N11O15S" @default.
- NCIT_C66944 NCIT_P366 "SGN-35" @default.
- NCIT_C66944 NCIT_P375 "Brentuximab Vedotin" @default.
- NCIT_C66944 NCIT_P399 "530758" @default.
- NCIT_C66944 normalizedInformationContent "85.460608731874885" @default.
- NCIT_C66944 referenceCount "9" @default.
- NCIT_C66944 hasExactSynonym "ADC SGN-35" @default.
- NCIT_C66944 hasExactSynonym "Adcetris" @default.
- NCIT_C66944 hasExactSynonym "Anti-CD30 Antibody-Drug Conjugate SGN-35" @default.
- NCIT_C66944 hasExactSynonym "Anti-CD30 Monoclonal Antibody-MMAE SGN-35" @default.
- NCIT_C66944 hasExactSynonym "Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35" @default.
- NCIT_C66944 hasExactSynonym "BRENTUXIMAB VEDOTIN" @default.
- NCIT_C66944 hasExactSynonym "Brentuximab Vedotin" @default.
- NCIT_C66944 hasExactSynonym "SGN-35" @default.
- NCIT_C66944 hasExactSynonym "cAC10-vcMMAE" @default.
- NCIT_C66944 inSubset NCIT_C116977 @default.
- NCIT_C66944 inSubset NCIT_C116978 @default.
- NCIT_C66944 inSubset NCIT_C128784 @default.
- NCIT_C66944 inSubset NCIT_C157711 @default.
- NCIT_C66944 inSubset NCIT_C157712 @default.
- NCIT_C66944 inSubset NCIT_C176424 @default.
- NCIT_C66944 inSubset NCIT_C177537 @default.
- NCIT_C66944 inSubset NCIT_C186327 @default.
- NCIT_C66944 inSubset NCIT_C186328 @default.
- NCIT_C66944 inSubset NCIT_C186341 @default.
- NCIT_C66944 inSubset NCIT_C63923 @default.
- NCIT_C66944 type Class @default.
- NCIT_C66944 isDefinedBy ncit.owl @default.
- NCIT_C66944 label "Brentuximab Vedotin" @default.
- NCIT_C66944 subClassOf NCIT_C129821 @default.
- NCIT_C66944 subClassOf NCIT_C129823 @default.
- NCIT_C66944 subClassOf NCIT_C1512 @default.
- NCIT_C66944 subClassOf NCIT_C158973 @default.
- NCIT_C66944 subClassOf NCIT_C163758 @default.
- NCIT_C66944 subClassOf NCIT_C164005 @default.
- NCIT_C66944 subClassOf NCIT_C1908 @default.
- NCIT_C66944 subClassOf NCIT_C1909 @default.
- NCIT_C66944 subClassOf NCIT_C274 @default.
- NCIT_C66944 subClassOf NCIT_C307 @default.
- NCIT_C66944 subClassOf NCIT_C308 @default.
- NCIT_C66944 subClassOf NCIT_C66944 @default.